0001551152 false Common Stock, $0.01 Par Value ABBV 0001551152 2021-04-16 2021-04-16 0001551152 us-gaap:CommonStockMember exch:XNYS 2021-04-16 2021-04-16 0001551152 exch:XCHI us-gaap:CommonStockMember 2021-04-16 2021-04-16 0001551152 abbv:SeniorNotes0.500Percentdue2021Member exch:XNYS 2021-04-16 2021-04-16 0001551152 abbv:SeniorNotes1.500Percentdue2023Member exch:XNYS 2021-04-16 2021-04-16 0001551152 abbv:SeniorNotes1.375Percentdue2024Member exch:XNYS 2021-04-16 2021-04-16 0001551152 abbv:SeniorNotes1.250Percentdue2024Member exch:XNYS 2021-04-16 2021-04-16 0001551152 abbv:SeniorNotes0.750Percentdue2027Member exch:XNYS 2021-04-16 2021-04-16 0001551152 abbv:SeniorNotes2.125Percentdue2028Member exch:XNYS 2021-04-16 2021-04-16 0001551152 abbv:SeniorNotes2.625Percentdue2028Member exch:XNYS 2021-04-16 2021-04-16 0001551152 abbv:SeniorNotes2.125Percentdue2029Member exch:XNYS 2021-04-16 2021-04-16 0001551152 abbv:SeniorNotes1.250Percentdue2031Member exch:XNYS 2021-04-16 2021-04-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares











Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): April 16, 2021




(Exact Name of Registrant as Specified in its Charter)



Delaware   001-35565   32-0375147
(State or other Jurisdiction
of Incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)



1 North Waukegan Road

North Chicago, Illinois 60064-6400

(Address of principal executive offices) (Zip Code)


Registrant’s telephone number, including area code: (847) 932-7900


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class   Trading Symbol(s)   Name of each exchange on which
Common Stock, $0.01 Par Value   ABBV   New York Stock Exchange
Chicago Stock Exchange
0.500% Senior Notes due 2021   ABBV21C   New York Stock Exchange
1.500% Senior Notes due 2023   ABBV23B   New York Stock Exchange
1.375% Senior Notes due 2024   ABBV24   New York Stock Exchange
1.250% Senior Notes due 2024   ABBV24B   New York Stock Exchange
0.750% Senior Notes due 2027   ABBV27   New York Stock Exchange
2.125% Senior Notes due 2028   ABBV28   New York Stock Exchange
2.625% Senior Notes due 2028   ABBV28B   New York Stock Exchange
2.125% Senior Notes due 2029   ABBV29   New York Stock Exchange
1.250% Senior Notes due 2031   ABBV31   New York Stock Exchange


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨






Item 7.01 Regulation FD Disclosure.


On April 16, 2021, AbbVie Inc. delivered a notice of redemption to the holders of its 0.500% Senior Notes due 2021 (the “Notes”), announcing the redemption on May 1, 2021 of all of its outstanding Notes. A copy of the notice is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein in its entirety.


Item 9.01 Financial Statements and Exhibits.


(d) Exhibits


99.1   Notice of Redemption dated April 16, 2021.
104   The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).






Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: April 20, 2021 By: /s/ Robert A. Michael
Name: Robert A. Michael
Title: Executive Vice President, Chief Financial Officer




Common Stock, $0.01 Par Value ABBV

Exhibit 99.1




AbbVie Inc.


0.500% Senior Notes due 2021


CUSIP No. 00287YDE6 (ISIN XS2117754247) / U0029QBK1 (ISIN XS2117754163) / 00287YDL0 (ISIN XS2125913603)*


Pursuant to Section 11.4 of the Base Indenture, dated as of November 8, 2012, between AbbVie Inc., a Delaware corporation (the “Issuer”), and U.S. Bank National Association, as trustee (the “Trustee”), as supplemented by Supplemental Indenture No. 9, dated as of May 14, 2020, among the Issuer, the Trustee, Elavon Financial Services DAC, U.K. Branch, as paying agent, and U.S. Bank National Association, as transfer agent and registrar, and as further amended or supplemented prior to the date hereof, notice is hereby given that, on May 1, 2021 (the “Redemption Date”), €539,018,000 aggregate principal amount of the Issuer’s outstanding 0.500% Senior Notes due 2021 (the “Notes”) will be redeemed pursuant to the terms of the Notes (the “Redemption”) at 100% of the principal amount of the Notes, plus accrued and unpaid interest on such principal amount to, but excluding, the Redemption Date (collectively, the “Redemption Price”).


On the Redemption Date, the Redemption Price will become due and payable. Unless the Issuer defaults in the payment of the Redemption Price, interest will cease to accrue on any Notes that have been called for redemption on and after the Redemption Date.


Notes called for redemption must be surrendered to the Trustee at the address specified below to collect payment of the Redemption Price:


If By Mail:


Elavon Financial Services DAC, U.K. Branch

125 Old Broad Street

London EC2N 1AR

United Kingdom

Attention: MBS Relationship Management


* No representation is made as to the accuracy or correctness of the CUSIP numbers listed herein or printed on the Notes. It is included solely for the convenience of the holders of the Notes.


Date: April 16, 2021By: AbbVie Inc.


For holders of Notes who have not established an exemption, payments made upon the Redemption of the Notes may be subject to U.S. federal backup withholding of 24% of the payments to be made, as and to the extent required by the provisions of the U.S. Internal Revenue Code of 1986, as amended. To establish an exemption from such backup withholding, holders of Notes should submit a completed and signed Internal Revenue Service Form W-9 (or applicable Form W-8) when surrendering their Notes for payment.